Treatment of hyperactivity in children with pervasive developmental disorders.
Scahill
Lawrence
L
Child Study Center, Yale University, New Haven, CT, USA. lawrence.scahill@yale.edu
Pachler
Maryellen
M
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000547:Amantadine / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000150:complications*; D002665:Child Psychiatry / Q000379:methods; D015259:Dopamine Agents / Q000627:therapeutic use; D016316:Guanfacine / Q000627:therapeutic use; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D018579:Patient Selection; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D000697:Central Nervous System Stimulants; D015259:Dopamine Agents; D009292:Narcotic Antagonists; D008774:Methylphenidate; D016316:Guanfacine; D009271:Naltrexone; D000547:Amantadine